

***** STN Columbus *****

FILE 'HOME' ENTERED AT 08:59:45 ON 21 JAN 2006

=> index biosci
FILE 'DRUGMONOG', ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS
FULL ESTIMATED COST
INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGXONOGZ, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 09:00:09 ON 21 JAN 2006

70 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> s microparticle (p) (surfactant or surface) (p) coat?

- 0* FILE ADISNEWS
 - 3 FILE ANABSTR
 - 1* FILE ANTE
 - 0* FILE AQUALINE
 - 1 FILE AQUASCI
 - 8* FILE BIOENG
 - 23 FILE BIOSIS
 - 29* FILE BIOTECHABS
 - 29* FILE BIOTECHDS
 - 12* FILE BIOTECHNO
 - 2 FILE CABA
 - 189 FILE CAPLUS
 - 2* FILE CEABA-VTB
 - 1* FILE CIN
 - 1 FILE CROPU
 - 3 FILE DDFU
 - 12 FILE DGENE
 - 5 FILE DISSABS
 - 10 FILE DRUGU
- 27 FILES SEARCHED...
- 15 FILE EMBASE
 - 9* FILE ESBIOBASE
 - 1* FILE FEDRIP
 - 0* FILE FOMAD
 - 0* FILE FOREGE
 - 0* FILE FROSTI
 - 0* FILE FSTA
 - 161 FILE IFIPAT
 - 3 FILE JICST-EPLJUS
 - 0* FILE KOSMET
 - 4 FILE LIFESCI
 - 16 FILE MEDLINE
 - 3* FILE NTIS
 - 0* FILE NUTRACEUT
 - 1 FILE OCEAN
 - 83* FILE PASCAL

50 FILES SEARCHED...

- 0* FILE PHARMAML
 - 3 FILE PHIN
 - 6 FILE PROMT
 - 21 FILE SCISEARCH
 - 8 FILE TOXCENTER
 - 1447 FILE USPATFULL
 - 155 FILE USPAT2
 - 0* FILE WATER
 - 827 FILE WPIDS
- 68 FILES SEARCHED...
- 7 FILE WP1FV
 - 827 FILE WPINDEX

36 FILES HAVE ONE OR MORE ANSWERS, 70 FILES SEARCHED IN STNINDEX

L1 QUE MICROPARTICLE (P) (SURFACTANT OR SURFACE) (P) COAT?

=> s l1 (p) protein

- 0* FILE ADISNEWS
- 0* FILE ANTE
- 0* FILE AQUALINE
- 1* FILE BIOENG
- 4 FILE BIOSIS
- 10* FILE BIOTECHABS

<-----User Break----->

=> s l1 (p) control?

- 0* FILE ADISNEWS
- 0* FILE ANTE
- 0* FILE AQUALINE
- 1 FILE AQUASCI
- 5* FILE BIOENG
- 7 FILE BIOSIS

<-----User Break----->

=> s l1 (p) encapsulat?

- 8* FILE BIOTECHDS
 - 0* FILE ADISNEWS
 - 0* FILE ANTE
 - 0* FILE AQUALINE
 - 1* FILE BIOENG
 - 4 FILE BIOSIS
 - 4* FILE BIOTECHABS
 - 4* FILE BIOTECHDS
 - 1* FILE BIOTECHNO
 - 2 FILE CAPLUS
 - 0* FILE CEABA-VTB
 - 0* FILE CIN
 - 1 FILE DDFU
 - 1 FILE DISSABS
 - 1 FILE DRUGU
 - 1 FILE EMBASE
 - 0* FILE ESBIOBASE
 - 0* FILE FEDRIP
- 31 FILES SEARCHED...
- 0* FILE FOMAD

0* FILE FOREGE
0* FILE FROSTI
0* FILE FSTA
44 FILE IFIPAT
0* FILE KOMET
1 FILE MEDLINE
0* FILE NTIS
0* FILE NUTRACEUT
9* FILE PASCAL
0* FILE PHARMAML
1 FILE PROMT
1 FILE SCISEARCH
2 FILE TOXCENTER
841 FILE USPATFULL
75 FILE USPAT2
65 FILES SEARCHED...
0* FILE WATER
13 FILE WPIDS
13 FILE WPINDEX

20 FILES HAVE ONE OR MORE ANSWERS, 70 FILES SEARCHED IN STINDEX

L2 QUE L1 (P) ENCAPSULAT?

=> d rank
F1 841 USPATFULL
F2 75 USPAT2
F3 44 IFIPAT
F4 13 WPIDS
F5 13 WPINDEX
F6 9* PASCAL
F7 4 BIOSIS
F8 4* BIOTECHABS
F9 4* BIOTECHDS
F10 2 CAPLUS
F11 2 TOXCENTER
F12 1 DDFU
F13 1 DISSABS
F14 1 DRUGU
F15 1 EMBASE
F16 1 MEDLINE
F17 1 PROMT
F18 1 SCISEARCH
F19 1* BIOENG
F20 1* BIOTECHNO

=> file f1-f9
COST IN U.S. DOLLARS
FULL ESTIMATED COST
SINCE FILE ENTRY TOTAL
3.66 3.87

FILE 'USPATFULL' ENTERED AT 09:04:00 ON 21 JAN 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 09:04:00 ON 21 JAN 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'IFIPAT' ENTERED AT 09:04:00 ON 21 JAN 2006
COPYRIGHT (C) 2006 IFI CLAIMS(R) Patent Services (IFI)
FILE 'WPIDS' ENTERED AT 09:04:00 ON 21 JAN 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION
FILE 'WPINDEX' ACCESS NOT AUTHORIZED
FILE 'PASCAL' ENTERED AT 09:04:00 ON 21 JAN 2006
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2006 INIST-CNRS. All rights reserved.
FILE 'BIOSIS' ENTERED AT 09:04:00 ON 21 JAN 2006
Copyright (c) 2006 The Thomson Corporation
FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED
FILE 'BIOTECHDS' ENTERED AT 09:04:00 ON 21 JAN 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION
<-----User Break----->
SEARCH ENDED BY USER
SEARCH ENDED BY USER
=> file hits
COST IN U.S. DOLLARS
FULL ESTIMATED COST
SINCE FILE ENTRY TOTAL
11.91 15.78
FILE 'USPATFULL' ENTERED AT 09:04:23 ON 21 JAN 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
FILE 'USPAT2' ENTERED AT 09:04:23 ON 21 JAN 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
FILE 'IFIPAT' ENTERED AT 09:04:23 ON 21 JAN 2006
COPYRIGHT (C) 2006 IFI CLAIMS(R) Patent Services (IFI)
FILE 'WPIDS' ENTERED AT 09:04:23 ON 21 JAN 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION
FILE 'WPINDEX' TEMPORARILY UNAVAILABLE
FILE 'PASCAL' ENTERED AT 09:04:23 ON 21 JAN 2006
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2006 INIST-CNRS. All rights reserved.
FILE 'BIOSIS' ENTERED AT 09:04:23 ON 21 JAN 2006
Copyright (c) 2006 The Thomson Corporation
FILE 'BIOTECHABS' TEMPORARILY UNAVAILABLE

FILE 'BIOTECHDS' ENTERED AT 09:04:23 ON 21 JAN 2006
 COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'CAPLUS' ENTERED AT 09:04:23 ON 21 JAN 2006
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'TOXCENTER' ENTERED AT 09:04:23 ON 21 JAN 2006
 COPYRIGHT (C) 2006 ACS

FILE 'DFU' ACCESS NOT AUTHORIZED

FILE 'DISSABS' ENTERED AT 09:04:23 ON 21 JAN 2006
 COPYRIGHT (C) 2006 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'DRUGU' ENTERED AT 09:04:23 ON 21 JAN 2006
 COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'EMBASE' ENTERED AT 09:04:23 ON 21 JAN 2006
 Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'MEDLINE' ENTERED AT 09:04:23 ON 21 JAN 2006

FILE 'PROMT' ENTERED AT 09:04:23 ON 21 JAN 2006
 COPYRIGHT (C) 2006 Gale Group. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 09:04:23 ON 21 JAN 2006
 Copyright (c) 2006 The Thomson Corporation

FILE 'BJOENG' ENTERED AT 09:04:23 ON 21 JAN 2006
 COPYRIGHT (C) 2006 Cambridge Scientific Abstracts (CSA)

FILE 'BIOTECHNO' ENTERED AT 09:04:23 ON 21 JAN 2006
 COPYRIGHT (C) 2006 Elsevier Science B.V., Amsterdam. All rights reserved.
 You have requested a file that you do not have permission to use. To
 arrange for access to this file, contact the Help Desk. Enter "HELP
 STN" for information on contacting the nearest STN Help Desk by
 telephone or via SEND in the STNMAIL file.

FIELD CODE - 'AND' OPERATOR ASSUMED 'OPARTICLE (P) '
 PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
 FIELD CODE - 'AND' OPERATOR ASSUMED 'SURFACE' (P) COAT?'
 PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
 FIELD CODE - 'AND' OPERATOR ASSUMED 'L1 (P) ENCAPSULA'
 PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
 FIELD CODE - 'AND' OPERATOR ASSUMED 'OPARTICLE (P) '
 PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
 FIELD CODE - 'AND' OPERATOR ASSUMED 'SURFACE' (P) COAT?'
 PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
 FIELD CODE - 'AND' OPERATOR ASSUMED 'L1 (P) ENCAPSULA'
 L3 1002 L2

=> dup rem l3
 PROCESSING COMPLETED FOR L3
 L4 899 DUP REM L3 (103 DUPLICATES REMOVED)

=> s l4 and protein
 L5 846 L4 AND PROTEIN

=> d his
 (FILE 'HOME' ENTERED AT 08:59:45 ON 21 JAN 2006)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
 AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS,
 CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB,
 DRUGMONO2, DRUGU, EMBAL, EMBASE,' ENTERED AT 09:00:09 ON 21 JAN 2006
 SEA MICROPARTICLE (P) (SURFACTANT OR SURFACE) (P) COAT?

 0* FILE ADISNEWS
 3 FILE ANABSTR
 1* FILE ANTE
 0* FILE AQUALINE
 1 FILE AQUASCI
 8* FILE BIOENG
 23 FILE BIOSIS
 29* FILE BIOTECHABS
 29* FILE BIOTECHDS
 12* FILE BIOTECHNO
 2 FILE CABA
 189 FILE CAPLUS
 2* FILE CEABA-VTB
 1* FILE CIN
 1 FILE CROPU
 3 FILE DDFU
 12 FILE DGENE
 5 FILE DISSABS
 10 FILE DRUGU
 15 FILE EMBASE
 9* FILE EMBASE
 1* FILE ESBIOBASE
 0* FILE FOMAD
 0* FILE FOREG
 0* FILE FROSTI
 0* FILE FSTA
 161 FILE IFIPAT

L1

3 FILE JICST-EPLUS
0* FILE KOSMET
4 FILE LIFESCI
16 FILE MEDLINE
3* FILE NTIS
0* FILE NUTRACEUT
1 FILE OCEAN
83* FILE PASCAL
0* FILE PHARMAML
3 FILE PHIN
6 FILE PROMT
21 FILE SCISEARCH
8 FILE TOXCENTER
1447 FILE USPATFULL
155 FILE USPAT2
0* FILE WATER
827 FILE WPIDS
7 FILE WP1FV
827 FILE WPINDEX

QUE MICROPARTICLE (P) (SURFACTANT OR SURFACE) (P) COAT?

SEA L1 (P) PROTEIN

0* FILE ADISNEWS
0* FILE ANTE
0* FILE AQUALINE
1* FILE BIOENG
4 FILE BIOSIS
10* FILE BIOTECHABS
10* FILE BIOTECHDS
SEA L1 (P) CONTROL?

0* FILE ADISNEWS
0* FILE ANTE
0* FILE AQUALINE
1 FILE AQUASCI
5* FILE BIOENG
7 FILE BIOSIS
8* FILE BIOTECHABS
8* FILE BIOTECHDS
SEA L1 (P) ENCAPSULAT?

0* FILE ADISNEWS
0* FILE ANTE
0* FILE AQUALINE
1* FILE BIOENG
4 FILE BIOSIS
4* FILE BIOTECHABS
4* FILE BIOTECHDS
1* FILE BIOTECHNO
2 FILE CAPJUS
0* FILE CEABA-VTB
0* FILE CIN
1 FILE DDFU
1 FILE DISSABS
1 FILE DRUGU
1 FILE EMBASE

0* FILE ESBIOBASE
0* FILE FEDRIP
0* FILE FOMAD
0* FILE FOREGE
0* FILE FROSTI
0* FILE FSTA
44 FILE IFIPAT
0* FILE KOSMET
1 FILE MEDLINE
0* FILE NTIS
0* FILE NUTRACEUT
9* FILE PASCAL
0* FILE PHARMAML
1 FILE PROMT
1 FILE SCISEARCH
2 FILE TOXCENTER
841 FILE USPATFULL
75 FILE USPAT2
0* FILE WATER
13 FILE WPIDS
13 FILE WPINDEX
L2 QUE L1 (P) ENCAPSULAT?

FILE 'USPATFULL, USPAT2, IFIPAT, WPIDS, PASCAL, BIOSIS, BIOTECHDS'
ENTERED AT 09:04:00 ON 21 JAN 2006
FILE 'USPATFULL, USPAT2, IFIPAT, WPIDS, PASCAL, BIOSIS, BIOTECHDS,
CAPJUS, TOXCENTER, DISSABS, DRUGU, EMBASE, MEDLINE, PROMT, SCISEARCH,
BIOENG, BIOTECHNO' ENTERED AT 09:04:23 ON 21 JAN 2006
1002 S L2
L3 899 DUP REM L3 (103 DUPLICATES REMOVED)
L4 846 S L4 AND PROTEIN
L5
=> s 15 and pharmaceutical
L6 814 L5 AND PHARMACEUTICAL
=> sort l6 py
SORT ENTIRE ANSWER SET? (Y)/N:y
PROCESSING COMPLETED FOR L6
L7 814 SORT L6 PY
=> d 17 trial 1
L7 ANSWER 1 OF 814 WPIDS COPYRIGHT 2006 THE THOMSON CORP ON STN
AN 2003-278270 [27] WPIDS
CR 2003-229409 [22]
DNC C2003-072620
T1 New Peyer's patch or M-cell targeting ligand, for facilitating the
transport of e.g. drugs (such as, analgesics, insulin, antisease
oligonucleotides or chemotherapy agents) or carriers through the human
intestinal epithelium.
DC B04 D16
1C 1CN A61K038-08; A61K038-10; C07K007-08; C12N015-09; C12P021-02
ICS A61K009-127; A61K009-14; A61K009-51; A61K035-76; A61K038-00;
A61K038-04; A61K039-00; A61K039-39; A61K047-48; A61K048-00;
C07H021-04; C07K005-083; C07K005-093; C07K005-097; C07K005-103;
C07K005-117; C07K007-02; C07K014-00; C07K014-005; C07K017-02;

MC C01: B04-B03C; B04-B04C; B04-C01; B04-E03F; B04-E06; B04-F1000E; B04-F1100E; B04-J03A; B04-N03B0E; B04-N04A; B12-M11; B12-M11F; B14-C01; B14-S03; B14-S11; D05-C11; D05-H07; D05-H12A; D05-H17A
PNC 7
CYC 101

=> d 17 bib ab 814 .

L7 ANSWER 814 OF 814 USPATFULL ON STN
AN 2006:3490 USPATFULL
TI Non-anaphylactogenic IgE fusion proteins
IN Morsey, Mohamad A., Niantic, CT, UNITED STATES
PA Brown, Tracy M., Ashaway, RI, UNITED STATES
PFI Pfizer, Inc., New York, NY, UNITED STATES (U.S. corporation)
PFI Pfizer Products, Inc., Groton, CT, UNITED STATES (U.S. corporation)
PI US 2006002943 A1 20060105
AI US 2005-221203 A1 20050907 (11)
RLI Continuation of Ser. No. US 2002-152190, filed on 21 May 2002, PENDING
PRAI US 2001-292638P 20010522 (60)
DT Utility
FS APPLICATION
LREP SCULLY SCOTT MURPHY & PRESSER, PC, 400 GARDEN CITY PLAZA, SUITE 300, GARDEN CITY, NY, 11530, US
CI/MN Number of Claims: 42
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.QNT 2778

AB The present invention provides compositions and methods for the use of antigenic peptides derived from the Fc portion of the epsilon heavy chain of IgE molecules from two unrelated species as vaccines for the treatment and prevention of IgE-mediated allergic disorders. In particular, the invention provides compositions for the treatment and prevention of IgE-mediated allergic disorders comprising an immunogenic amount of one or more antigenic peptides.

=> d 17 bib ab 2-10

L7 ANSWER 2 OF 814 WPIDS COPYRIGHT 2006 THE THOMSON CORP ON STN
AN 2004-132758 [13] WPIDS
DNC C2004-052966
TI Bioactive sol-gel solution useful for repairing hard and soft tissue defects comprises biocompatible polymer, gelable inorganic base material, and calcium and phosphorous molecular species.
DC A96 B04 D16
IN BRENNAN, A; CUEVAS, B; HATCHER, B M; SEEGER, C
PA (BRENNAN, A; CUEVAS, B; HATCHER, B M; SEEGER, C
SEEGER, C; (UYFL) UNIV FLORIDA

CYC 102

PI WO 2004005533 A2 20040115 (200413)* EN 74
RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS
LU MC MW NZ NL OA PT RO SE SI SK SL SZ TR TZ UG ZM ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK
DM DZ EC EE ES FI GB GD GE GH GM GR HU ID IL IN IS JP KE KG KP KR
KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT

RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM
ZW
US 2004052861 A1 20040318 (200421)
AU 2003251899 A1 20040123 (200459)
WO 2004005533 A2 WO 2003-US21962 20030710; US 2004052861 A1 Provisional US
ADT 2002-395186P 20020710, US 2003-616884 20030710; AU 2003251899 A1 AU
2003-251899 20030710
FDT AU 2003251899 A1 Based on WO 2004005533
PRAI US 2002-395186P 20020710; US 2003-616884 20030710
AB WO2004005533 A UPAB: 20040223
WO2004005533 (a), a gelable inorganic base material (b), and at least one calcium and phosphorous molecular species (c), is new.
DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:
(1) a bioactive glass composite comprising (a) and (c); and
(2) formation of a bioactive glass involving mixing (a) - (c), and hydrolyzing the mixture.
ACTIVITY - None given.
MECHANISM OF ACTION - None given.
USE - For repairing hard and soft tissue defects (claimed).
ADVANTAGE - The solution has a pH of 1 - 7 (preferably 1.2 - 2), viscosity of 1.5 - 6 Pa sec at 25 deg. C, and is stable for at least 30 days at 25 deg. C.
Dwg. 0/27

L7 ANSWER 3 OF 814 USPATFULL ON STN

AN 1998:124213 USPATFULL
TI Method of delivering a lipid-coated condensed-phase microparticle composition

IN Fernandez, Julio M., Rochester, MN, United States
Knudson, Mark B., Shoreview, MN, United States
PA ACCES Pharmaceuticals, Inc., Dallas, TX, United States (U.S. corporation)

PI US 5820879 19981013

AI US 1995-444244 19950518 (8)

RLI Continuation-in-part of Ser. No. US 1994-250464, filed on 27 May 1994 which is a continuation-in-part of Ser. No. US 1993-17681, filed on 12 Feb 1993, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Kishore, Gollamudi S.

LREP Dehlinger, Peter J., Mohr, Judy M.

CI/MN Number of Claims: 27

ECL Exemplary Claim: 1

DRWN 43 Drawing Figure(s); 15 Drawing Page(s)

LN.QNT 2337

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of delivering a therapeutic compound to an in vivo target site having a selected pH, temperature, ligand concentration or binding-molecule characteristic. The method includes entrapping the therapeutic compound in an encapsulated microparticle composition that, when exposed to a selected target stimulus related to pH, temperature, radiation, or the presence of a selected ligand or ion-channel activator, decondenses to release compound into the target site. The encapsulated microparticle composition consists of a condensed-phase particle matrix containing the compound to be delivered in entrapped form, and a stimulus-responsive lipid bilayer membrane formed around the

matrix. Localized perturbation of the lipid membrane, and influx of monovalent counterions into the polymer matrix, in response to the selected target stimulus, causes matrix swelling and compound release from the particles.

L7 ANSWER 4 OF 814 USPATFULL on STN
AN 1998:154516 USPATFULL
TI Lipid-coated condensed-phase microparticle composition
IN Fernandez, Julio M., Rochester, MN, United States
PA Access Pharmaceuticals, Inc., Dallas, TX, United States (U.S. corporation)
PI US 5753261 19980519
AI US 1995-443402 19950517 (8)
RLI Continuation-in-part of Ser. No. US 1994-250646, filed on 27 May 1994 which is a continuation-in-part of Ser. No. US 1993-17681, filed on 12 Feb 1993, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Kishore, Gollamudi S.
LREP Dehlinger, Peter J., Mohr, Judy M.
CLMN Number of Claims: 20
ECL Exemplary Claim: 1

DRWN 43 Drawing Figure(s); 15 Drawing Page(s)

LN.CNT 2233

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A microparticle composition for use in compound delivery, when the composition is exposed to a selected target stimulus related to pH, temperature, radiation, or the presence of a selected ligand or ion-channel activator, is disclosed. The composition includes a condensed-phase particle matrix containing the compound to be delivered in entrapped form, and a stimulus-responsive lipid bilayer membrane formed around the matrix. Localized perturbation of the lipid membrane, and influx of monovalent counterions into the polymer matrix, in response to the selected target stimulus, causes matrix swelling and compound release from the particles.

L7 ANSWER 5 OF 814 USPATFULL on STN
AN 1999:159488 USPATFULL
TI Treatment and prevention of cancer by administration of derivatives of human chorionic gonadotropin
IN Gallo, Robert C., Bethesda, MD, United States
PA Bryant, Joseph, Rockville, MD, United States
Lunardi-Iskandar, Yanto, Gaithersburg, MD, United States
University of Maryland Biotechnology Institute, College Park, MD, United States (U.S. corporation)
PI US 5997871 19991207
AI US 1996-709925 19960909 (8)
RLI Continuation-in-part of Ser. No. US 1996-669676, filed on 24 Jun 1996, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Hutzell, Paula K.; Assistant Examiner: Bansal, Geetha P.
LREP Barrett, William A., Hultquist, Steven J.
CLMN Number of Claims: 38
ECL Exemplary Claim: 1

DRWN 17 Drawing Figure(s); 10 Drawing Page(s)

LN.CNT 2288

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods of treating or preventing cancer by administration of human chorionic gonadotropin, .beta.-human chorionic gonadotropin or a peptide containing a sequence of a portion of .beta.-human chorionic gonadotropin. In a preferred embodiment, the invention provides methods of treating or preventing Kaposi's Sarcoma, breast cancer or prostate cancer. In another preferred embodiment, the invention relates to .beta.-human chorionic gonadotropin peptides for treatment or prevention of cancer. The invention further provides assays for the utility of particular human chorionic gonadotropin preparations in the treatment or prevention of cancer. **Pharmaceutical*** compositions and methods of administration are also provided.

L7 ANSWER 6 OF 814 USPATFULL on STN

AN 1999:155886 USPATFULL

TI Nucleotide and ***protein*** sequences of lats genes and methods based thereon

IN Xu, Tian, Guilford, CT, United States
Tao, Wufan, Branford, CT, United States
Wang, Weiye, New Haven, CT, United States
Zhang, Sheng, New Haven, CT, United States
Yu, Wan, Guilford, CT, United States
Yale University, New Haven, CT, United States (U.S. corporation)

PA US 5994503 19991130

AI US 1995-41111 19950327 (8)

DT Utility

FS Granted

EXNAM Primary Examiner: Mosher, Mary E.

LREP Pennie & Edmonds LLP

CLMN Number of Claims: 67

ECL Exemplary Claim: 1

DRWN 15 Drawing Figure(s); 43 Drawing Page(s)

LN.CNT 6419

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a tumor suppressor gene, termed large tumor suppressor (lats), and methods for identifying tumor suppressor genes. The method provides nucleotide sequences of lats genes, and amino acid sequences of their encoded proteins, as well as derivatives (e.g., fragments) and analogs thereof. In a specific embodiment, the lats ***protein*** is a human ***protein***. The invention further relates to fragments (and derivatives and analogs thereof) of lats which comprise one or more domains of a lats ***protein***. Antibodies to lats, its derivatives and analogs, are additionally provided. Methods of production of the lats proteins, derivatives and analogs, e.g., by recombinant means, are also provided. Therapeutic and diagnostic methods and ***pharmaceutical*** compositions are provided. The invention also relates to recombinant plants and animals and methods of increasing the growth of edible plants and animals. In specific examples, isolated lats genes, from Drosophila, mouse, and human, and the sequences thereof, are provided.

L7 ANSWER 7 OF 814 USPATFULL on STN

AN 1999:151394 USPATFULL

TI Nucleotide and amino acid sequences of C4-2, a tumor suppressor gene, and methods of use thereof

IN Murphy, Gerald P., Seattle, WA, United States
 Boynton, Alton L., Redmond, WA, United States
 Sehgal, Anil, Seattle, WA, United States
 PA Northwest Biotherapeutics LLC, Seattle, WA, United States (U.S. corporation)
 PI US 5990294 19991123
 AI US 1996-744905 19961108 (8)
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Huff, Sheela; Assistant Examiner: Eyler, Yvonne
 LREP Pennie & Edmonds LLP
 CLMN Number of Claims: 5
 ECL Exemplary Claim: 2
 DRWN 22 Drawing Figure(s); 7 Drawing Page(s)
 LN.CNT 2707
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The present invention relates to the discovery, identification and characterization of a novel tumor suppressor gene C4-2. The invention encompasses nucleotide sequences of the C4-2 gene and amino acid sequences of its encoded ***protein*** product(s), as well as derivatives and analogs thereof. The invention also encompasses the production of C4-2 proteins and antibodies. The invention further encompasses therapeutic compositions and methods of diagnosis and therapy.

L7 ANSWER 8 OF 814 USPATFULL on STN
 AN 1999:146754 USPATFULL
 TI CDK2 interactions
 IN Yang, MeiJia, East Lyme, CT, United States
 Nandabalan, Krishnan, Guilford, CT, United States
 PA Schultz, Vincent Peter, Madison, CT, United States
 CuraGen Corporation, New Haven, CT, United States (U.S. corporation)
 PI US 5986055 19991116
 AI US 1997-969106 19971113 (8)
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Degen, Nancy; Assistant Examiner: Schwartzman, Robert
 LREP Elrif, Ivor R.Mintz, Levin, Cohn, Ferris, Glovsky and Popeo P.C., Morancy, Michel
 CLMN Number of Claims: 8
 ECL Exemplary Claim: 3
 DRWN 9 Drawing Figure(s); 16 Drawing Page(s)
 LN.CNT 4836
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The present invention relates to complexes of the CDK2 ***protein*** with proteins identified as interacting with CDK2 by a modified yeast two hybrid assay system. The proteins identified to interact with CDK2 are cyclin H, cyclin I, ERH, and two gene products, hsReq-1 and hsReq-2, which are splice variants of the gene hsReq. Thus, the invention provides complexes of CDK2 and cyclin H, cyclin I, ERH, hsReq-1, and hsReq-2, and derivatives, fragments and analogs thereof. The invention also provides nucleic acids encoding the hsReq-1 and hsReq-2, and proteins and derivatives, fragments and analogs thereof. Methods of screening the complexes for efficacy in treating and/or preventing certain diseases and disorders, particularly cancer, atherosclerosis and neurodegenerative disease are also provided.

L7 ANSWER 9 OF 814 USPATFULL on STN
 AN 1999:137459 USPATFULL
 TI 53BP2 complexes
 IN Nandabalan, Krishnan, Guilford, CT, United States
 Yang, MeiJia, East Lyme, CT, United States
 PA Schulz, Vincent Peter, Madison, CT, United States (U.S. corporation)
 PI US 5977311 19991102
 AI US 1997-935450 19970923 (8)
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Hutzell, Paula K.; Assistant Examiner: Worrall, Timothy A.
 LREP Elrif, Ivor R.Mintz, Levin, Cohn, Ferris, Glovsky and Popeo
 CLMN Number of Claims: 10
 ECL Exemplary Claim: 1
 DRWN 10 Drawing Figure(s); 21 Drawing Page(s)
 LN.CNT 5316
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The present invention relates to complexes of the 53BP2 ***protein*** with proteins identified as interacting with 53BP2 by a yeast two hybrid assay system. The proteins identified to interact with 53BP2 are .beta.-tubulin, p62, hnRNP G, and three gene products, 53BP2-IP1, 53BP2-IP2, and 53BP2-IP3 encoded, in part, by the EST R72810 sequence. Thus, the invention provides complexes of 53BP2 and .beta.-tubulin, p62, hnRNP G, 53BP2-IP1, 53BP2-IP2, and 53BP2-IP3 and derivatives, fragments and analogs thereof. The invention also provides the 53BP2-IP1, 53BP2-IP2 and 53BP2-IP3 genes and proteins and derivatives, fragments and analogs thereof. Methods of screening the complexes for efficacy in treating and/or preventing certain diseases and disorders, particularly cancer, autoimmune disease and neurodegenerative disease are also provided.

L7 ANSWER 10 OF 814 USPATFULL on STN
 AN 1999:137023 USPATFULL
 TI Phenotypic conversion of drug-resistant bacteria to drug-sensitivity
 IN Altman, Sidney, Hamden, CT, United States
 Guerrier-Takada, Cecilia, New Haven, CT, United States
 PA Yale University, New Haven, CT, United States (U.S. corporation)
 PI US 5976874 19991102
 AI US 1997-911886 19970815 (8)
 PRAI US 1996-23675P 19960816 (60)
 US 1997-53774P 19970725 (60)
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Achutamurthy, Ponnathapu; Assistant Examiner: Moore, William W.
 LREP Arnell Golden & Gregory, LLP
 CLMN Number of Claims: 14
 ECL Exemplary Claim: 1
 DRWN 3 Drawing Figure(s); 5 Drawing Page(s)
 LN.CNT 950
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB External guide sequences ("EGS") can be used to promote RNasease P-mediated cleavage of RNA transcribed from plasmids and other genetic elements which confer drug resistance on bacterial cells. Such cleavage can render the bacteria drug sensitive. In a preferred embodiment, a

vector encoding an EGS is administered to an animal or human harboring antibiotic resistant bacterial cells such that the EGS is expressed in the bacterial cells, the EGS promotes RNAase P-mediated cleavage of RNA involved in conferring antibiotic resistance to the cells, and the cells are rendered antibiotic sensitive. A preferred form of administration is via inoculation of the animal or human with cells containing genes for appropriate EGSs on promiscuous plasmids. These plasmids will spread quickly through the antibiotic-resistant population of bacterial cells, thereby making the cells susceptible to antibiotic therapy.

=> d his

(FILE 'HOME' ENTERED AT 08:59:45 ON 21 JAN 2006)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONCGZ, DRUGO, EMBAL, EMBASE, ...' ENTERED AT 09:00:09 ON 21 JAN 2006

SEA MICROPARTICLE (P) (SURFACTANT OR SURFACE) (P) COAT?

0* FILE ADISNEWS
3 FILE ANABSTR
1* FILE ANTE
0* FILE AQUALINE
1 FILE AQUASCI
8* FILE BIOENG
23 FILE BIOSIS
29* FILE BIOTECHABS
29* FILE BIOTECHDS
12* FILE BIOTECHNO
2 FILE CABA
189 FILE CAPLUS
2* FILE CEABA-VTB
1* FILE CIN
1 FILE CROPU
3 FILE DDFU
12 FILE DGENE
5 FILE DISSABS
10 FILE DRUGU
15 FILE EMBASE
9* FILE ESBIOBASE
1* FILE FEDRIP
0* FILE FOREG
0* FILE FOMAD
0* FILE FROSTI
0* FILE FSTA
161 FILE IFIPAT
3 FILE JICST-EPLJUS
0* FILE KOSMET
4 FILE LIFESCI
16 FILE MEDLINE
3* FILE NTIS
0* FILE NUTRACEUT
1 FILE OCEAN
83* FILE PASCAL
0* FILE PHARMAML

3 FILE PHIN
6 FILE PROMT
21 FILE SCISEARCH
8 FILE TOXCENTER
1447 FILE USPATFULL
155 FILE USPAT2
0* FILE WATER
827 FILE WPIDS
7 FILE WPIFV
827 FILE WPINDEX
QUE MICROPARTICLE (P) (SURFACTANT OR SURFACE) (P) COAT?

SEA L1 (P) PROTEIN

0* FILE ADISNEWS
0* FILE ANTE
0* FILE AQUALINE
1 FILE AQUASCI
5* FILE BIOENG
7 FILE BIOSIS
8* FILE BIOTECHABS
8* FILE BIOTECHDS
SEA L1 (P) ENCAPSULAT?

0* FILE ADISNEWS
0* FILE ANTE
0* FILE AQUALINE
1* FILE BIOENG
4 FILE BIOSIS
4* FILE BIOTECHABS
4* FILE BIOTECHDS
1* FILE BIOTECHNO
2 FILE CAPLUS
0* FILE CEABA-VTB
0* FILE CIN
1 FILE DDFU
1 FILE DISSABS
1 FILE DRUGU
1 FILE EMBASE
0* FILE ESBIOBASE
0* FILE FEDRIP
0* FILE FOMAD
0* FILE FOREG
0* FILE FROSTI
0* FILE FSTA
44 FILE IFIPAT
0* FILE KOSMET
1 FILE MEDLINE

L1

```

0* FILE NTIS
0* FILE NUTRACEUT
9* FILE PASCAL
0* FILE PHARMAML
1 FILE PROMT
1 FILE SCISEARCH
2 FILE TOXCENTER
841 FILE USPATFULL
75 FILE USPAT2
0* FILE WATER
13 FILE WPIDS
13 FILE WPINDEX
12 QUE L1 (P) ENCAPSULAT?
-----
FILE 'USPATFULL, USPAT2, IFIPAT, WPIDS, PASCAL, BIOSIS, BIOTECHDS'
ENTERED AT 09:04:00 ON 21 JAN 2006
FILE 'USPATFULL, USPAT2, IFIPAT, WPIDS, PASCAL, BIOSIS, BIOTECHDS,
CAPUS, TOXCENTER, DISSABS, DRUGU, EMBASE, MEDLINE, PROMT, SCISEARCH,
BIOENG, BIOTECHNO' ENTERED AT 09:04:23 ON 21 JAN 2006
1002 S L2
899 DUP REM L3 (103 DUPLICATES REMOVED)
846 S L4 AND PROTEIN
814 S L5 AND PHARMACEUTICAL
814 SORT L6 PY
L3
L4
L5
L6
L7
=> s l7 and polysaccharide
1 FILES SEARCHED...
L8 426 L7 AND POLYSACCHARIDE
=> s l8 and stabiliz?
L9 407 L8 AND STABILIZ?
=> d l9 bib ab 1-10
L9 ANSWER 1 OF 407 USPATFULL on STN
AN 2006:15798 USPATFULL
TI Human phosphatase RET31, and variants thereof
IN Jackson, Donald G., Lawrenceville, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Foder, John N., Belle Mead, NJ, UNITED STATES
Mintier, Gabe, Hightstown, NJ, UNITED STATES
Lee, Liana, North Brunswick, NJ, UNITED STATES
Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES
Siemers, Nathan, Pennington, NJ, UNITED STATES
Bol, David, Langhorne, PA, UNITED STATES
Suchard, Suzanne, Wilmington, DE, UNITED STATES
Schieven, Gary, Lawrenceville, NJ, UNITED STATES
Finger, Joshua, San Marcos, CA, UNITED STATES
Todderrud, C. Gordon, Newtown, PA, UNITED STATES
Bassolino, Donna, Hamilton, NJ, UNITED STATES
Krystek, Stanley, Ringoes, NJ, UNITED STATES
Banas, Dana, Hamilton, NJ, UNITED STATES
McAtee, Patrick, Pennington, NJ, UNITED STATES
AI 2006014180 AI 20060119
US 2005-143984 AI 20050602 (11)
Division of Ser. No. US 2001-29345, filed on 20 Dec 2001, PENDING

```

```

PRAI US 2000-256868P 20001220 (60)
US 2001-280186P 20010330 (60)
US 2001-287735P 20010501 (60)
US 2001-295848P 20010605 (60)
US 2001-300465P 20010625 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O
BOX 4000, PRINCETON, NJ, 08543-4000, US
CLMN Number of Claims: 17
ECL Exemplary Claim: 1-25
DRWN 67 Drawing Page(s)
LN.CNT 29165
AB The present invention provides novel polynucleotides encoding human
phosphatase polypeptides, fragments and homologues thereof. Also
provided are vectors, host cells, antibodies, and recombinant and
synthetic methods for producing said polypeptides. The invention further
relates to diagnostic and therapeutic methods for applying these novel
human phosphatase polypeptides to the diagnosis, treatment, and/or
prevention of various diseases and/or disorders related to these
polypeptides, particularly cardiovascular diseases and/or disorders. The
invention further relates to screening methods for identifying agonists
and antagonists of the polynucleotides and polypeptides of the present
invention.
L9 ANSWER 2 OF 407 USPATFULL on STN
AN 2006:3923 USPATFULL
TI Human tumor necrosis factor receptor TR-17
IN Ruben, Steven M., Brookville, MD, UNITED STATES
Baker, Kevin P., Darnestown, MD, UNITED STATES
PA Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S.
corporation)
PI US 2006003380 AI 20060105
AI US 2005-221849 AI 20050909 (11)
RLI Division of Ser. No. US 2001-961376, filed on 25 Sep 2001, PENDING
Continuation-in-part of Ser. No. US 2000-533822, filed on 24 Mar 2000,
ABANDONED
PRAI US 2000-235991P 20000926 (60)
US 2000-254874P 20001213 (60)
US 2000-188208P 20000310 (60)
DT Utility
FS APPLICATION
LREP HUMAN GENOME SCIENCES INC, INTELLECTUAL PROPERTY DEPT., 14200 SHADY
GROVE ROAD, ROCKVILLE, MD, 20850, US
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 13416
AB The present invention relates to a novel ***protein***, TR17, which
is a member of the tumor necrosis factor (TNF) receptor superfamily. In
particular, isolated nucleic acid molecules are provided encoding the
human TR17. TR17 polypeptides are also provided as anti TR17 antibodies
and vectors, host cells and recombinant methods for producing the same.
The invention further relates to methods of killing cells using the
antibodies of the invention.
L9 ANSWER 3 OF 407 USPATFULL on STN

```

AN 2006:3910 USPATFULL
TI Polynucleotides encoding a novel human Kupffer cell receptor
protein, BGS-18

IN Wu, Shujian, Langhorne, PA, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES

PI US 2006003367 AI 20060105
AI US 2003-152697 AI 20050614 (11)
PRAI US 2004-58006P 20040615 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000, US

CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 9 Drawing Page(s)
LN.CNT 10766

AB The present invention provides novel polynucleotides encoding BGS-18 polypeptide, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel BGS-18 polypeptide to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

L9 ANSWER 4 OF 407 USPATFULL on STN
AN 2005:298951 USPATFULL
TI Nucleotide and ***protein*** sequences of Nogo genes and methods based thereon

IN Schwab, Martin E., Zurich, SWITZERLAND
Chen, Maio S., Zurich, SWITZERLAND
The University of Zurich (non-U.S. corporation)

PA US 2005260616 AI 20051124
AI US 2003-44899 AI 20050126 (11)
RLI Continuation of Ser. No. US 2001-830972, filed on 24 Sep 2001, PENDING A 371 of International Ser. No. WO 1999-US26160, filed on 5 Nov 1999

PRAI US 1998-107446P 19981106 (60)
DT Utility
FS APPLICATION
LREP JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017, US

CLMN Number of Claims: 42
ECL Exemplary Claim: 1
DRWN 41 Drawing Page(s)
LN.CNT 4543

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to the gene, Nogo, its encoded ***protein*** products, as well as derivatives and analogs thereof. Production of Nogo proteins, derivatives, and antibodies is also provided. The invention further relates to therapeutic compositions and methods of diagnosis and therapy.

L9 ANSWER 5 OF 407 USPATFULL on STN
AN 2005:298522 USPATFULL
TI Soluble glycosaminoglycanases and methods of preparing and using soluble

glycosaminoglycanases

IN Bookbinder, Louis H., San Diego, CA, UNITED STATES
Kundu, Anirban, San Diego, CA, UNITED STATES
Frost, Gregory I., Del Mar, CA, UNITED STATES
Haller, Michael F., San Diego, CA, UNITED STATES
Keller, Gilbert A., Belmont, CA, UNITED STATES
Dylan, Tyler M., San Diego, CA, UNITED STATES
Halozyme, Inc., San Diego, CA, UNITED STATES (U.S. corporation)

PI US 2005260186 AI 20051124
AI US 2005-65716 AI 20050223 (11)
RLI Continuation-in-part of Ser. No. US 2004-795095, filed on 5 Mar 2004, PENDING

PRAI US 2003-452360P 20030305 (60)
DT Utility
FS APPLICATION
LREP DIA PIPER RUDNICK GRAY CARY US, LLP, 4365 EXECUTIVE DRIVE, SUITE 1100, SAN DIEGO, CA, 92121-2133, US

CLMN Number of Claims: 255
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 10953

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to the discovery of novel soluble neutral active Hyaluronidase glycoproteins (SHASEGP), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active SHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of SHASEGP. The invention further comprises sialated and pegylated forms of a recombinant SHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant SHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.

L9 ANSWER 6 OF 407 USPATFULL on STN
AN 2005:292986 USPATFULL
TI Antibodies that immunospecifically bind to B lymphocyte stimulator

IN Ruben, Steven M., Brookeville, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
Choi, Gil H., Rockville, MD, UNITED STATES
Vaughan, Tristan, Cambridge, UNITED KINGDOM
Hilbert, David, Bethesda, MD, UNITED STATES

PI US 2005255532 AI 20051117
AI US 2005-54515 AI 20050210 (11)
RLI Continuation-in-part of Ser. No. US 2002-293418, filed on 14 Nov 2002, PENDING Continuation-in-part of Ser. No. US 2001-880748, filed on 15 Jun 2001, PENDING Continuation-in-part of Ser. No. US 2001-880748, filed on 15 Jun 2001, PENDING

PRAI US 2004-543296P 20040211 (60)
US 2004-580347P 20040618 (60)
US 2001-331469P 20011116 (60)
US 2001-340817P 20011219 (60)
US 2000-212210P 20000616 (60)
US 2000-240816P 20001017 (60)

US 2001-276248P 20010316 (60)
US 2001-277379P 20010321 (60)
US 2001-293499P 20010525 (60)
US 2000-212210P 20000616 (60)
US 2000-240816P 20001017 (60)
US 2001-276248P 20010316 (60)
US 2001-277379P 20010321 (60)
US 2001-293499P 20010525 (60)

DT
UTILITY
FS
APPLICATION
LREP
HUMAN GENOME SCIENCES INC, INTELLECTUAL PROPERTY DEPT., 14200 SHADY GROVE ROAD, ROCKVILLE, MD, 20850, US
CLMN
Number of Claims: 20
ECL
Exemplary Claim: 1
DRWN
16 Drawing Page(s)
LN.CNT 20962

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB
The present invention relates to antibodies and related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention also relates to methods and compositions for detecting or diagnosing a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate function of B Lymphocyte Stimulator comprising antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention further relates to methods and compositions for preventing, treating or ameliorating a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate B Lymphocyte Stimulator function comprising administering to an animal an effective amount of one or more antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator.

L9
ANSWER 7 OF 407 USPATFULL on STN
AN
2005:280894 USPATFULL
TI
90 human secreted proteins
IN
Ruben, Steven M., Brookville, MD, UNITED STATES
Soppet, Daniel R., Centerville, VA, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Olsen, Henrik S., Gaithersburg, MD, UNITED STATES
Young, Paul E., Gaithersburg, MD, UNITED STATES
Greene, John M., Gaithersburg, MD, UNITED STATES
Ferrie, Ann M., Painted Post, NY, UNITED STATES
Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Ni, Jian, Germantown, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Brewer, Laurie A., St. Paul, MN, UNITED STATES
Janat, Fouad, Westerly, RI, UNITED STATES
Birise, Charles E., North Potomac, MD, UNITED STATES
PA
Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)
PI
US 2005244845 A1 20051103
AI
US 2004-996501 A1 20041112 (10)
RLI
Continuation of Ser. No. US 2003-621363, filed on 18 Jul 2003, ABANDONED
Continuation of Ser. No. US 2001-969730, filed on 4 Oct 2001, ABANDONED
Continuation-in-part of Ser. No. US 2001-774639, filed on 1 Feb 2001,
GRANTED, Pat. No. US 6806351 Continuation of Ser. No. US 1999-244112,
filed on 4 Feb 1999, ABANDONED Continuation-in-part of Ser. No. WO

1998-US16235, filed on 4 Aug 1998, PENDING
PRA1
US 2000-238291P 20001006 (60)
US 1997-55386P 19970805 (60)
US 1997-54807P 19970805 (60)
US 1997-55312P 19970805 (60)
US 1997-55309P 19970805 (60)
US 1997-54798P 19970805 (60)
US 1997-55310P 19970805 (60)
US 1997-54806P 19970805 (60)
US 1997-54804P 19970805 (60)
US 1997-54803P 19970805 (60)
US 1997-54808P 19970805 (60)
US 1997-55311P 19970805 (60)
US 1997-55986P 19970818 (60)
US 1997-55970P 19970818 (60)
US 1997-56563P 19970819 (60)
US 1997-56557P 19970819 (60)
US 1997-56731P 19970819 (60)
US 1997-56365P 19970819 (60)
US 1997-56367P 19970819 (60)
US 1997-56370P 19970819 (60)
US 1997-56364P 19970819 (60)
US 1997-56366P 19970819 (60)
US 1997-56732P 19970819 (60)
US 1997-56371P 19970819 (60)

DT
UTILITY
FS
APPLICATION
LREP
HUMAN GENOME SCIENCES INC, INTELLECTUAL PROPERTY DEPT., 14200 SHADY GROVE ROAD, ROCKVILLE, MD, 20850, US
CLMN
Number of Claims: 23
ECL
Exemplary Claim: 1
DRWN
2 Drawing Page(s)
LN.CNT 26443

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB
The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

L9
ANSWER 8 OF 407 USPATFULL on STN
AN
2005:274543 USPATFULL
TI
27 human secreted proteins
IN
Ruben, Steven M., Brookville, MD, UNITED STATES
Ni, Jian, Germantown, MD, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Shi, Yanggu, Gaithersburg, MD, UNITED STATES
Birise, Charles E., North Potomac, MD, UNITED STATES
Florence, Kimberly A., Rockville, MD, UNITED STATES
Komatsoulis, George A., Silver Spring, MD, UNITED STATES
Lafleur, David W., Washington, DC, UNITED STATES
Moore, Paul A., North Bethesda, MD, UNITED STATES
Olsen, Henrik S., Gaithersburg, MD, UNITED STATES

Young, Paul E., Gaithersburg, MD, UNITED STATES
Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S.)

PA
PI US 2005239099 AI 20051027
AI US 2004-963903 AI 20041014 (10)
RLI Continuation of Ser. No. US 2002-50882, filed on 18 Jan 2002, PENDING
Continuation of Ser. No. US 2000-661433, filed on 13 Sep 2000, PENDING
Continuation-in-part of Ser. No. WO 2000-US6783, filed on 16 Mar 2000,
PENDING
PRAI US 1999-125055P 19990318 (60)
DT Utility
FS APPLICATION
LREP HUMAN GENOME SCIENCES INC, INTELLECTUAL PROPERTY DEPT., 14200 SHADY
GROVE ROAD, ROCKVILLE, MD, 20850, US
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 19413

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

L9 ANSWER 9 OF 407 USPATFULL on STN
AN 2005:274542 USPATFULL
TI Novel hyaluronan-binding proteins and encoding genes
IN Hastings, Gregg A., Westlake Village, CA, UNITED STATES
Liau, Gene, Darnestown, MD, UNITED STATES
Tsifrina, Elena, Owings Mills, MD, UNITED STATES
Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S.)

PA
PI US 2005239098 AI 20051027
AI US 2004-960275 AI 20041008 (10)
RLI Division of Ser. No. US 1999-466778, filed on 20 Dec 1999, GRANTED, Pat.
No. US 6872546
PRAI US 1998-113871P 19981223 (60)
DT Utility
FS APPLICATION
LREP HUMAN GENOME SCIENCES INC, INTELLECTUAL PROPERTY DEPT., 14200 SHADY
GROVE ROAD, ROCKVILLE, MD, 20850, US
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 66 Drawing Page(s)
LN.CNT 19454

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to full-length WF-HABP, OE-HABP, and BM-HABP, novel members of the hyaluronan receptor family. The invention provides isolated nucleic acid molecules encoding human to full-length WF-HABP, OE-HABP, and BM-HABP receptors. Full-length WF-HABP, OE-HABP, and BM-HABP polypeptides are also provided, as are vectors, host cells and recombinant methods for

producing the same. The invention further relates to screening methods for identifying agonists and antagonists of full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP receptor activity. Also provided are diagnostic methods for detecting disease states related to the aberrant expression of full-length WF-HABP, OE-HABP, and BM-HABP receptors. Further provided are therapeutic methods for treating disease states including, but not limited to, proliferative conditions, metastasis, inflammation, ischemia, host defense dysfunction, immune surveillance dysfunction, arthritis, multiple sclerosis, autoimmunity, immune dysfunction, and allergy.

L9 ANSWER 10 OF 407 USPATFULL on STN
AN 2005:274503 USPATFULL
TI 67 human secreted proteins
IN Ruben, Steven M., Olney, MD, UNITED STATES
Fertie, Ann M., Painted Post, NY, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Florence, Kimberly, Rockville, MD, UNITED STATES
Carter, Kenneth C., North Potomac, MD, UNITED STATES
Soppet, Daniel R., Centerville, VA, UNITED STATES
Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Florence, Charles, Rockville, MD, UNITED STATES
Young, Paul E., Gaithersburg, MD, UNITED STATES
NL, Jian, Germantown, MD, UNITED STATES
Endress, Gregory A., Florence, MA, UNITED STATES
Feng, Ping, Gaithersburg, MD, UNITED STATES
Janat, Fouad, Westerly, RI, UNITED STATES
Birse, Charles, North Potomac, MD, UNITED STATES

PI US 2005239059 AI 20051027
AI US 2001-949925 AI 20010912 (9)
RLI Continuation-in-part of Ser. No. WO 1999-US1621, filed on 27 Jan 1999, PENDING
Continuation-in-part of Ser. No. US 1999-363044, filed on 29 Jul 1999, ABANDONED
Continuation-in-part of Ser. No. WO 1999-US1621, filed on 27 Jan 1999, PENDING
US 2000-232150P 20000912 (60)
PRAI US 1998-73170P 19980130 (60)
US 1998-73167P 19980130 (60)
US 1998-73165P 19980130 (60)
US 1998-73164P 19980130 (60)
US 1998-73162P 19980130 (60)
US 1998-73161P 19980130 (60)
US 1998-73160P 19980130 (60)
US 1998-73159P 19980130 (60)
US 1998-73170P 19980130 (60)
US 1998-73167P 19980130 (60)
US 1998-73165P 19980130 (60)
US 1998-73164P 19980130 (60)
US 1998-73162P 19980130 (60)
US 1998-73161P 19980130 (60)
US 1998-73160P 19980130 (60)
US 1998-73159P 19980130 (60)

DT Utility
FS APPLICATION
LREP HUMAN GENOME SCIENCES INC, INTELLECTUAL PROPERTY DEPT., 14200 SHADY
GROVE ROAD, ROCKVILLE, MD, 20850, US
CLMN Number of Claims: 23
ECL Exemplary Claim: 1

DRWN 4 Drawing Page(s)

LN.CNT 21427

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

=> s 19 not (polynucleotide or nucleic or dna)

L10 3 L9 NOT (POLYNUCLEOTIDE OR NUCLEIC OR DNA)

=> d 110 bib ab 1-10

L10 ANSWER 1 OF 3 USPTAFULL on STN

AN 2004:227044 USPTAFULL

TI Biodegradable microparticles that ***stabilize*** and control the release of proteins

IN Alavattam, Sreedhara, Columbus, OH, UNITED STATES

PI Brody, Richard S., Worthington, OH, UNITED STATES

AI US 2004:75429 AI 20040909

AI US 2003-750475 AI 20031231 (10)

PRAI US 2002-437351P 20021231 (60)

US 2003-486842P 20030711 (60)

DT Utility

FS APPLICATION

LREP BATELLE MEMORIAL INSTITUTE, 505 KING AVENUE, COLUMBUS, OH, 43201-2693

CLMN Number of Claims: 28

ECL Exemplary Claim: 1

DRWN 6 Drawing Page(s)

LN.CNT 1152

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed herein are biodegradable microparticle compositions, and methods for the generation of biodegradable and biocompatible microparticles that ***stabilize*** proteins and also control the kinetics of release of proteins over a period of several weeks to several months under physiological conditions.

L10 ANSWER 2 OF 3 USPTAFULL on STN

AN 1998:1124213 USPTAFULL

TI Method of delivering a lipid-coated condensed-phase microparticle composition

IN Fernandez, Julio M., Rochester, MN, United States

KNudson, Mark B., Shoreview, MN, United States

PA ACCESS Pharmaceuticals, Inc., Dallas, TX, United States (U.S. corporation)

PI US 5820879 19981013

AI US 1995-444244 19950518 (8)

RLI Continuation-in-part of Ser. No. US 1994-250464, filed on 27 May 1994

which is a continuation-in-part of Ser. No. US 1993-17681, filed on 12 Feb 1993, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Kishore, Gollamudi S.

LREP Dehlinger, Peter J., Mohr, Judy M.

CLMN Number of Claims: 27

ECL Exemplary Claim: 1

DRWN 43 Drawing Figure(s); 15 Drawing Page(s)

LN.CNT 2337

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of delivering a therapeutic compound to an in vivo target site having a selected pH, temperature, ligand concentration or binding-molecule characteristic. The method includes entrapping the therapeutic compound in an encapsulated microparticle composition that, when exposed to a selected target stimulus related to pH, temperature, radiation, or the presence of a selected ligand or ion-channel activator, decondenses to release compound into the target site. The encapsulated microparticle composition consists of a condensed-phase particle matrix containing the compound to be delivered in entrapped form, and a stimulus-responsive lipid bilayer membrane formed around the matrix. Localized perturbation of the lipid membrane, and influx of monovalent counterions into the polymer matrix, in response to the selected target stimulus, causes matrix swelling and compound release from the particles.

L10 ANSWER 3 OF 3 USPTAFULL on STN

AN 1998:54516 USPTAFULL

TI Lipid-coated condensed-phase microparticle composition

IN Fernandez, Julio M., Rochester, MN, United States

KNudson, Mark B., Shoreview, MN, United States

PA ACCESS Pharmaceuticals, Inc., Dallas, TX, United States (U.S. corporation)

PI US 5753261 19980519

AI US 1995-443402 19950517 (8)

RLI Continuation-in-part of Ser. No. US 1994-250464, filed on 27 May 1994

which is a continuation-in-part of Ser. No. US 1993-17681, filed on 12 Feb 1993, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Kishore, Gollamudi S.

LREP Dehlinger, Peter J., Mohr, Judy M.

CLMN Number of Claims: 20

ECL Exemplary Claim: 1

DRWN 43 Drawing Figure(s); 15 Drawing Page(s)

LN.CNT 2233

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A microparticle composition for use in compound delivery, when the composition is exposed to a selected target stimulus related to pH, temperature, radiation, or the presence of a selected ligand or ion-channel activator, is disclosed. The composition includes a condensed-phase particle matrix containing the compound to be delivered in entrapped form, and a stimulus-responsive lipid bilayer membrane formed around the matrix. Localized perturbation of the lipid membrane, and influx of monovalent counterions into the polymer matrix, in response to the selected target stimulus, causes matrix swelling and compound release from the particles.

=> d his

(FILE 'HOME' ENTERED AT 08:59:45 ON 21 JAN 2006)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPIUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGNOGZ, DRUGJ, EMBAL, EMBASE, ...', ENTERED AT 09:00:09 ON 21 JAN 2006
SEA MICROPARTICLE (P) (SURFACTANT OR SURFACE) (P) COAT?

0* FILE ADISNEWS
3 FILE ANABSTR
1* FILE ANTE
0* FILE AQUALINE
1 FILE AQUASCI
8* FILE BIOENG
23 FILE BIOSIS
29* FILE BIOTECHABS
29* FILE BIOTECHDS
12* FILE BIOTECHNO
2 FILE CABA
189 FILE CAPIUS
2* FILE CEABA-VTB
1* FILE CIN
1 FILE CROPU
3 FILE DDFU
12 FILE DGENE
5 FILE DISSABS
10 FILE DRUGJ
15 FILE EMBASE
9* FILE ESBIOBASE
1* FILE FEDRIP
0* FILE FOMAD
0* FILE FOREGE
0* FILE FROSTI
0* FILE FSTA
161 FILE IFIPAT
3 FILE JICST-EPIJUS
0* FILE KOSMET
4 FILE LIFESCI
16 FILE MEDLINE
3* FILE NTIS
0* FILE NUTRACEUT
1 FILE OCEAN
83* FILE PASCAL
0* FILE PHARMAML
3 FILE PHIN
6 FILE PROMT
21 FILE SCISEARCH
8 FILE TOXCENTER
1447 FILE USPATFULL
155 FILE USPAT2
0* FILE WATER
827 FILE WPIDS
7 FILE WPIDV
827 FILE WPINDEX

SEA L1 (P) PROTEIN

L1

0* FILE ADISNEWS
0* FILE ANTE
0* FILE AQUALINE
1* FILE BIOENG
4 FILE BIOSIS
10* FILE BIOTECHABS
10* FILE BIOTECHDS
SEA L1 (P) CONTROL?

0* FILE ADISNEWS
0* FILE ANTE
0* FILE AQUALINE
1 FILE AQUASCI
5* FILE BIOENG
7 FILE BIOSIS
8* FILE BIOTECHABS
8* FILE BIOTECHDS
SEA L1 (P) ENCAPSULAT?

0* FILE ADISNEWS
0* FILE ANTE
0* FILE AQUALINE
1* FILE BIOENG
4* FILE BIOTECHABS
4* FILE BIOTECHDS
1* FILE BIOTECHNO
2 FILE CAPIUS
0* FILE CEABA-VTB
0* FILE CIN
1 FILE DDFU
1 FILE DISSABS
1 FILE DRUGJ
1 FILE EMBASE
0* FILE ESBIOBASE
0* FILE FEDRIP
0* FILE FOMAD
0* FILE FOREGE
0* FILE FROSTI
0* FILE FSTA
44 FILE IFIPAT
0* FILE KOSMET
1 FILE MEDLINE
0* FILE NTIS
0* FILE NUTRACEUT
9* FILE PASCAL
0* FILE PHARMAML
1 FILE PROMT
1 FILE SCISEARCH
2 FILE TOXCENTER
841 FILE USPATFULL
75 FILE USPAT2
0* FILE WATER
13 FILE WPIDS
13 FILE WPINDEX

SEA L1 (P) ENCAPSULAT?

L2

FILE 'USPATFULL, USPAT2, IFIPAT, WPIDS, PASCAL, BIOSIS, BIOTECHDS'
ENTERED AT 09:04:00 ON 21 JAN 2006
FILE 'USPATFULL, USPAT2, IFIPAT, WPIDS, PASCAL, BIOSIS, BIOTECHDS,
CAPJUS, TOXCENTER, DISSABS, DRUGU, EMBASE, MEDLINE, PROMT, SCISEARCH,
BIOENG, BIOTECHNO' ENTERED AT 09:04:23 ON 21 JAN 2006

L3 1002 S L2
L4 899 DUP REM L3 (103 DUPLICATES REMOVED)
L5 846 S L4 AND PROTEIN
L6 814 S L5 AND PHARMACEUTICAL
L7 814 SORT L6 PY
L8 426 S L7 AND POLYSACCHARIDE
L9 407 S L8 AND STABILIZ?
L10 3 S L9 NOT (POLYNUCLEOTIDE OR NUCLEIC OR DNA)

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	97.41	113.19

STN INTERNATIONAL LOGOFF AT 09:12:10 ON 21 JAN 2006